Movement Alert｜Twist Bioscience Corp Falls 6.31% in After-Hours Trading, Earlier rating initiations and Lilly TuneLab collaboration remain in focus

Market Focus10-30

On October 30, Twist Bioscience Corp fell 6.31% in After-Hours Trading, trading at $161.78/share, with turnover of $4.3725 million.

The latest public information indicates the market was still digesting the company’s recent investment bank coverage and its previously announced collaboration with Eli Lilly’s TuneLab, but no stronger new catalyst was evident in the most recent update tied to the move.

Earlier disclosures showed Jefferies initiated coverage with a Hold rating and a $150 price target, while UBS initiated with a Neutral rating and a $144 price target. Separately, Twist Bioscience Corp said it would provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform, with the collaboration centered on antibody drug discovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment